Clinical Study To Evaluate The Efficacy And Safety Of Psorlyn Tablet And Psorlyn Oil In Psoriasis W.S.R. Kitibha
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change in Pasi score.
研究概览
简要总结
Psoriasis is one of the common, chronic, autoimmune skin disorder is first evident in approximately one third of affected individuals within the first 2 decade of life. When the onset occurring during childhood about 50% have positive family history of the disease and girls are more frequently affected. The mode of transmission is unknown; a multifactorial type of inheritance has been proposed. There is an association with histocompatibility antigens (HLA).
Modern medicine science uses coltar, PUVA (Psoralen and ultraviolet A), corticosteroids and anti mitotic drug for the treatment of psoriasis and it has serious systemic side effects like liver, kidney failure, bone marrow depletion etc. Thus our duty to establish a safer and effective line of treatment for human welfare. Ayurveda may provides long lasting effects, results and better life to patient through its uniqueness.
Psorlyn tablet and Psorlyn oil are proposed to evaluate the efficacy and utility in treatment of psoriasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 10.00 Year(s) 至 16.00 Year(s)（—）
- 性别
- All
入选标准
- •Children age group between 10 – 16 years of either sex.
- •Children having classical sign and symptom and diagnosed as psoriasis.
- •Patient should be capable of obeying the instruction related to course of therapy.
排除标准
- •Patient with k/c/o any chronic systemic illness and allergic disorders.
- •Patient with k/c/o any other chronic skin disorder except psoriasis.
- •Patient not fulfilling the inclusion criteria.
- •Patient/Attendant not willing to give written consent for participation in the research study.
结局指标
主要结局
Change in Pasi score.
时间窗: 3 months
次要结局
- To evaluate the safety of trial drug (Tablet Psorlyn & Oil Psorlyn).